{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:46:06Z","timestamp":1761007566343,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,5,23]],"date-time":"2002-05-23T00:00:00Z","timestamp":1022112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report on 2 patients with idiopathic Parkinson's disease who experienced marked improvement in symptoms following the addition of itraconazole to current cabergoline treatment. Plasma levels of cabergoline were analyzed in one of the patients and increased to approximately 300% during treatment with itraconazole, which paralleled major clinical improvement. \u00a9 2002 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10250","type":"journal-article","created":{"date-parts":[[2002,12,4]],"date-time":"2002-12-04T09:20:29Z","timestamp":1038993629000},"page":"1360-1362","source":"Crossref","is-referenced-by-count":9,"title":["Cabergoline plasma concentration is increased during concomitant treatment with itraconazole"],"prefix":"10.1002","volume":"17","author":[{"given":"Jakob","family":"Christensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,23]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00002"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00004"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00003"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549020-00009"},{"key":"e_1_2_5_7_2","unstructured":"WienkersL.In vitro screen for the identification of potential interactions of PNU\u2010142779 and the major human cytochrome P450 enzymes expressed in liver. Report no. a0016932. Kalamazoo MI: Pharmacia and Upjohn;1998."},{"key":"e_1_2_5_8_2","first-page":"1295","volume-title":"The pharmacological basis of therapeutics","author":"Bennett JE","year":"2001"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161001-00003"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1999.tb01059.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.184"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90038-2"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90191-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90167-8"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90066-2"},{"key":"e_1_2_5_16_2","series-title":"Recent developments in Parkinson's disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_5_17_2","unstructured":"RenouxA Gesson\u2010CholatI.Determination of the concentration of cabergoline in a single and multiple\u2010dose pharmacokinetics evaluation study in healthy elderly and young volunteers. Report no. P99133. Kalamazoo MI: Pharmacia and Upjohn;2000."},{"key":"e_1_2_5_18_2","unstructured":"RahimyM BolyardK KnuthD et al.Cabergoline (PNU\u2010124779): evaluation of single\u2010 and multiple\u2010dose pharmacokinetics in healthy young and elderly volunteers. Report no. 779\u2010CNS\u20100067\u20100022. Kalamazoo MI: Pharmacia and Upjohn;2000."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100278"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10250","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:25:12Z","timestamp":1760970312000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,23]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1002\/mds.10250"],"URL":"https:\/\/doi.org\/10.1002\/mds.10250","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2002,5,23]]}}}